Literature DB >> 21479074

Dose intensity in early-stage breast cancer: a community practice experience.

Robert L Bretzel1, Ralph Cameron, Marc Gustas, Maria A Garcia, Heather K Hoffman, Rosalind Malhotra, Karen Miller, Janine Prime, Anne Favret.   

Abstract

Although nodal status, grade, size, and receptor status play roles in determining breast cancer prognosis, there is increasing evidence that maintaining dose intensity of adjuvant chemotherapy increases disease-free survival rate.

Entities:  

Year:  2009        PMID： 21479074      PMCID： PMC2869188          DOI： 10.1200/JOP.091036

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  11 in total

1.  Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices.

Authors:  Nancy White; Cathy Maxwell; Jennifer Michelson; Cindi Bedell
Journal:  Cancer Nurs       Date:  2005 Jan-Feb       Impact factor: 2.592

2.  30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study.

Authors:  Gianni Bonadonna; Angela Moliterni; Milvia Zambetti; Maria Grazia Daidone; Silvana Pilotti; Luca Gianni; Pinuccia Valagussa
Journal:  BMJ       Date:  2005-01-13

Review 3.  The importance of dose intensity in the outcome of chemotherapy.

Authors:  W M Hryniuk
Journal:  Important Adv Oncol       Date:  1988

4.  Relative dose intensity: improving cancer treatment and outcomes.

Authors:  Cheryl Lenhart
Journal:  Oncol Nurs Forum       Date:  2005-07-01       Impact factor: 2.172

5.  Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care.

Authors:  B K Link; G T Budd; S Scott; E Dickman; D Paul; G Lawless; M W Lee; M Fridman; J Ford; W B Carter
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

6.  Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.

Authors:  V J Picozzi; B L Pohlman; V A Morrison; G D Lawless; M W Lee; R O Kerr; J M Ford; D J Delgado; M Fridman; W B Carter
Journal:  Oncology (Williston Park)       Date:  2001-10       Impact factor: 2.990

Review 7.  Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.

Authors:  Gary H Lyman
Journal:  J Natl Compr Canc Netw       Date:  2005-07       Impact factor: 11.908

8.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

Authors:  G Bonadonna; P Valagussa; A Moliterni; M Zambetti; C Brambilla
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

9.  Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.

Authors:  Gary H Lyman; David C Dale; Jeffrey Crawford
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

10.  Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.

Authors:  Jeffrey Crawford; David C Dale; Nicole M Kuderer; Eva Culakova; Marek S Poniewierski; Debra Wolff; Gary H Lyman
Journal:  J Natl Compr Canc Netw       Date:  2008-02       Impact factor: 11.908
View more
  2 in total

1.  Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.

Authors:  Esse I H Akpo; Irshaad R Jansen; Edith Maes; Steven Simoens
Journal:  Front Pharmacol       Date:  2017-09-13       Impact factor: 5.810

2.  Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment.

Authors:  Yoshitaka Saito; Yoh Takekuma; Takashi Takeshita; Tomohiro Oshino; Mitsuru Sugawara
Journal:  Sci Rep       Date:  2022-07-22       Impact factor: 4.996
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.